|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.890 HKD | +1.64% |
|
+1.12% | +17.32% |
| Jan. 15 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| Jan. 15 | CSPC Innovation Pharmaceutical Warns of Swing to 2025 Loss | MT |
| Capitalization | 113B 14.5B 12.36B 11.45B 10.77B 20.04B 1,320B 21.5B 132B 52.22B 627B 54.37B 53.26B 2,290B | P/E ratio 2025 * |
20.7x | P/E ratio 2026 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise value | 102B 13.11B 11.18B 10.36B 9.74B 18.13B 1,194B 19.45B 120B 47.23B 568B 49.18B 48.17B 2,071B | EV / Sales 2025 * |
3.33x | EV / Sales 2026 * | 3.09x |
| Free-Float |
70.45% | Yield 2025 * |
2.87% | Yield 2026 * | 3.14% |
| 1 day | +1.64% | ||
| 1 week | +1.12% | ||
| Current month | +17.32% | ||
| 1 month | +20.61% | ||
| 3 months | +9.65% | ||
| 6 months | +7.62% | ||
| Current year | +17.32% |
| 1 week | 9.56 |  | 9.96 |
| 1 month | 8.11 | | 10.16 |
| Current year | 8.38 | | 10.16 |
| 1 year | 4.33 | | 11.63 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 12.68 |
| 10 years | 3.08 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Cai
CEO | Chief Executive Officer | 46 | 2025-12-18 |
Qing Jie Wei
COO | Chief Operating Officer | 57 | 2025-12-18 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 45 | 2024-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 2011-08-25 |
Huai Yu Wang
BRD | Director/Board Member | 63 | 2010-09-30 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 2012-01-19 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.64% | +1.12% | +124.26% | +5.78% | 14.26B | |
| +2.31% | -0.74% | +43.52% | +211.33% | 932B | |
| -0.97% | -1.57% | +45.20% | +27.81% | 526B | |
| +0.53% | -2.90% | +24.82% | +45.04% | 378B | |
| -0.38% | +0.17% | +27.57% | +16.67% | 374B | |
| -1.35% | -7.03% | +20.68% | +20.84% | 282B | |
| +0.07% | -1.48% | +27.95% | +33.84% | 278B | |
| -4.02% | -1.16% | -34.82% | -22.56% | 272B | |
| +1.40% | -0.09% | +15.24% | +0.93% | 272B | |
| +2.23% | +2.78% | +23.04% | +29.56% | 178B | |
| Average | +0.08% | -0.04% | +31.75% | +36.92% | 350.61B | |
| Weighted average by Cap. | +0.25% | -0.40% | +28.00% | +71.21% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 30.71B 3.94B 3.36B 3.11B 2.92B 5.44B 358B 5.84B 35.9B 14.18B 170B 14.77B 14.47B 622B | 32.48B 4.17B 3.55B 3.29B 3.09B 5.76B 379B 6.18B 37.97B 15B 180B 15.62B 15.3B 658B |
| Net income | 5.52B 708M 604M 559M 526M 979M 64.46B 1.05B 6.46B 2.55B 30.65B 2.66B 2.6B 112B | 6B 770M 656M 608M 572M 1.06B 70.05B 1.14B 7.02B 2.77B 33.31B 2.89B 2.83B 122B |
| Net Debt | -10.8B -1.38B -1.18B -1.09B -1.03B -1.91B -126B -2.05B -12.62B -4.99B -59.92B -5.19B -5.09B -219B | -12.63B -1.62B -1.38B -1.28B -1.2B -2.24B -147B -2.4B -14.76B -5.83B -70.06B -6.07B -5.95B -256B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-21 | 9.890 $ | +1.64% | 58,136,368 |
| 26-01-20 | 9.730 $ | -0.10% | 67,927,020 |
| 26-01-19 | 9.740 $ | -0.92% | 104,416,300 |
| 26-01-16 | 9.830 $ | +0.31% | 79,718,560 |
| 26-01-15 | 9.800 $ | -0.10% | 94,825,600 |
Delayed Quote Hong Kong S.E., January 21, 2026 at 03:08 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
